Teva Introduces Irinotecan Hydrochloride Injection

February 28, 2008 – Teva Health Systems is pleased to announce the introduction and availability of Irinotecan Hydrochloride Injection. This product is AP Rated to Camptosar®* Injection. Irinotecan Hydrochloride Injection is available in 20 mg/mL, 40 mg, and 20 mg/mL, 100 mg in single dose amber polymer vials.“Teva offers a broad range of quality health systems generics from a single source,” states Jonathan Zalk, Director of Marketing. “We are pleased to announce this latest addition to our growing line.”Teva Health Systems is a part of Teva Pharmaceuticals, the leading pharmaceutical manufacturer for both new and total prescriptions. The company has an aggressive Research and Development effort and one of the best overall ANDA approval records in the industry.